| Literature DB >> 28584156 |
Julien Bador1,2, Catherine Neuwirth3,2, Nadège Grangier1, Marie Muniz1, Leslie Germé1, Jérémy Bonnet1, Vignesh-Guru Pillay1, Catherine Llanes2, Claire de Curraize1,2, Lucie Amoureux1,2.
Abstract
AxyXY-OprZ is an RND-type efflux system that confers innate aminoglycoside resistance to Achromobacter spp. We investigated here a putative TetR family transcriptional regulator encoded by the axyZ gene located upstream of axyXY-oprZ An in-frame axyZ gene deletion assay led to increased MICs of antibiotic substrates of the efflux system, including aminoglycosides, cefepime, fluoroquinolones, tetracyclines, and erythromycin, indicating that the product of axyZ negatively regulates expression of axyXY-oprZ Moreover, we identified an amino acid substitution at position 29 of AxyZ (V29G) in a clinical Achromobacter strain that occurred during the course of chronic respiratory tract colonization in a cystic fibrosis (CF) patient. This substitution, also detected in three other strains exposed in vitro to tobramycin, led to an increase in the axyY transcription level (5- to 17-fold) together with an increase in antibiotic resistance level. This overproduction of AxyXY-OprZ is the first description of antibiotic resistance acquisition due to modification of a chromosomally encoded mechanism in Achromobacter and might have an impact on the management of infected CF patients. Indeed, tobramycin is widely used for aerosol therapy within this population, and we have demonstrated that it easily selects mutants with increased MICs of not only aminoglycosides but also fluoroquinolones, cefepime, and tetracyclines.Entities:
Keywords: Achromobacter; AxyXY-OprZ; AxyZ; cystic fibrosis; efflux; tobramycin
Mesh:
Substances:
Year: 2017 PMID: 28584156 PMCID: PMC5527583 DOI: 10.1128/AAC.00290-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191